Update (June 13, 2026): Enflicoxib Field Study — Stable Responder Rates vs Declining Placebo, AEs Comparable to NSAID Class

TL;DR

Field study data from Salichs 2024 (n=109 dogs) show that enflicoxib (Daxocox), the once-weekly COX-2-selective NSAID, produced adverse event rates described as comparable to other NSAID reference compounds — alongside significantly higher CSS responder rates (71.6-74.6% enflicoxib vs 20.8-41.7% placebo) across the primary and secondary endpoints.

What just dropped

• Salichs and colleagues (2024) published the pivotal field study of enflicoxib in 109 dogs with OA randomised 3:1 (active:placebo). CSS (Clinical Signs Score) responder rates at assessed timepoints: 71.6%, 74.6%, and 71.6% for enflicoxib vs 41.7%, 33.3%, and 20.8% for placebo (p<0.05 at all timepoints). The report described AEs as comparable to those seen with other NSAIDs in the class. (https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1349901/full)
• EMA Daxocox EPAR confirms enflicoxib's pharmacotherapeutic classification as anti-inflammatory and anti-rheumatic, with EU authorisation (EMEA/V/C/005354, CVMP positive opinion 19 February 2021). (https://www.ema.europa.eu/en/medicines/veterinary/EPAR/daxocox)

Context

Enflicoxib (Daxocox) is unique within the canine NSAID landscape as a once-weekly oral COX-2-selective inhibitor. The extended dosing interval results from its pharmacokinetic profile, which provides sustained plasma concentrations over 7 days with a single tablet. For clients where daily tablet compliance is a challenge, the once-weekly schedule represents a practical advantage.

The Salichs 2024 field study shows that the placebo responder rate declined sharply across time (41.7% to 20.8%) while the enflicoxib group maintained consistent responder rates (71.6-74.6%), suggesting stable drug effect without tachyphylaxis across the study window. This pattern is clinically meaningful for managing expectations in long-term OA treatment.

The AE characterisation as "comparable to other NSAIDs" in the field study is consistent with enflicoxib's COX-2-selective mechanism, which shares the NSAID class profile. EMA authorisation confirms the regulatory tolerance conclusion.

Taken together, enflicoxib occupies a specific niche: for dogs tolerating NSAIDs well but where once-weekly convenience improves adherence, the field study data support a clinically meaningful and sustained analgesic effect.

What this changes in Enflicoxib (Daxocox) for Canine Osteoarthritis (https://www.thevoyage.ai/forvets/knowledge/enflicoxib-daxocox-canine-osteoarthritis)

This update consolidates the field study tolerability framing from the Salichs 2024 paper for the evergreen page, complementing the efficacy responder-rate data already cited there. The focus on the declining-placebo vs stable-enflicoxib pattern adds a treatment-durability narrative that supports longer-term OA management discussions.

References

1. Salichs M et al. 2024. Enflicoxib pivotal field study in canine OA: CSS responder rates and tolerability (n=109). Front Vet Sci 11:1349901. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1349901/full
2. European Medicines Agency. Daxocox (enflicoxib) EPAR. EMEA/V/C/005354. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/daxocox

Related reads

• Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID
• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence